進行非扁平上皮非小細胞肺がんの一次治療において、ペメトレキセド+白金製剤を含む化学療法への抗PD-L1抗体アテゾリズマブの併用効果を検証するIMpower132試験においてPFSを有意に延長【スイス・Roche】

Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer

 

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq®(atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone in the initial (first-line) treatment of advanced non-squamous non-small cell lung cancer (NSCLC). While a numerical improvement for the co-primary endpoint of overall survival (OS) was observed, statistical significance was not met at this interim analysis, and the study will continue as planned with final OS results expected next year. Safety for the Tecentriq and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination. These data will be presented at an upcoming medical meeting.

 


 


 

コメント

Leave a comment

Your email address will not be published.


*